[en] Although progress has been made through screening and vaccination against human papillomavirus (HPV), locally advanced (LACC) and metastatic cervical cancer continue to present significant therapeutic challenges. Indeed, the treatment strategies have remained largely unchanged for almost twenty years. In the LACC setting, recent research has focused on improving standard treatment (chemoradiation followed by brachytherapy), including neo-adjuvant chemotherapy (INTERLACE trial) or addition of an immune
checkpoint inhibitor (ICI) (ENGOT-Cx11 study). In metastatic disease, immunotherapy is also making strides,
encompassing ICIs in the first-line treatment; but also, tumour-infiltrating lymphocyte (TIL) transfer and
therapeutic vaccination are still in clinical trials. The antibody-drug conjugate (ADC) tisotumab vedotin has
demonstrated efficacy in second- or third-line therapy, while other ADCs targeting HER2 and TROP2 are
under investigation. These innovative treatments offer hope for improving survival outcomes in the cervical
cancer patient population.
Disciplines :
Oncology
Author, co-author :
Gennigens, Christine ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
LEBEAU, Alizée ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Language :
English
Title :
Emerging therapies in gynaecological cancers (part 1) : Locally advanced and metastatic cervical cancer
